InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,650.00
(
0.05%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.59
(
0.00%
)
Bitcoin
60,961.53
(
0.27%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 75

Monday, 03/26/2018 1:02:01 PM

Monday, March 26, 2018 1:02:01 PM

Post# of 438
CDTX reported positive Ph2 outcome for its antifungal during 3/18

Cash runway will not finance the two Ph3 studies it must run

will likely raise capital in 2018.

Value of equity is being impacted by the fact that all its competing treatments will be generic by the time the CDTX antifungal is ready for launch.

Equity is also being impacted by bearish sentiment for antibiotics in development. Market is uncertain about ample take-out values.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up